Avoid common mistakes on your manuscript.
The role of c-MET as member of the receptor tyrosine kinase superfamily in the signaling pathway of non-small cell lung cancer (NSCLC) has been extensively described [1, 2]. MET is overexpressed in up to 60% of NSCLC cases, and in tumors harboring MET mutations this molecular structure is directly targeted using tyrosine kinase inhibitors (TKI) for therapeutic purposes [3].
68Ga-EMP-100 is a novel PET ligand that addresses the tyrosine kinase c-MET and has already shown its applicability in patients with metastatic renal cell carcinoma [4].
We present a case of a 56-year-old female former smoker with stage IV EGFR mutation-positive NSCLC (lymphogenic, pulmonary, hepatic, and cerebral metastases. Stage: cT3, cN3, cM1b) and concomitant MET exon 14 skipping mutation. After multiple pretreatments including radiochemotherapy and additional systemic therapies with afatinib, crizotinib, osimertinib, and cabozantinib, the patient underwent 18F-FDG PET/CT for treatment monitoring purposes, where multiple pulmonary and hepatic metastases with high glucose consumption were noted (Fig. 1A, B). Moreover, the patient underwent 68Ga-EMP-100 PET/CT (6 days before 18F-FDG PET/CT) to further assess c-MET expression in these tumoral sites. Here, a highly heterogeneous c-MET expression was found with some lesions showing high c-MET expression, but also lesions with only slight or even barely any increased c-MET expression despite their high glucose consumption on 18F-FDG PET (see Fig. 1 A vs. C and Fig. 1 B vs. D). Overall, elevated tumor metabolism was not necessarily accompanied by high c-MET expression.
This case illustrates the heterogeneity of tumor molecular biology in the stage IV setting, and the potential of 68Ga-EMP-100 PET/CT for pre-therapeutic and non-invasive assessment of whole-body c-MET expression in NSCLC patients prior to c-MET targeting tyrosine kinase inhibitors such as cabozantinib [2, 5]. Tissue biopsies may underestimate the heterogeneity of tumor lesions. Molecular imaging may provide a broader assessment of the distribution and relevance of particular molecular features, such as the c-MET expression as assessed with 68Ga-EMP-100 PET/CT, and thus inform treatment priorities.
References
Murtuza A, Bulbul A, Shen JP, Keshavarzian P, Woodward BD, Lopez-Diaz FJ, et al. Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. Cancer Res. 2019;79(4):689–98.
Pasquini G, Giaccone G. C-MET inhibitors for advanced non-small cell lung cancer. Expert Opin Investig Drugs. 2018;27(4):363–75.
Markowitz JN, Fancher KM. Cabozantinib: a multitargeted oral tyrosine kinase inhibitor. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2018;38(3):357–69.
Mittlmeier LM, Todica A, Gildehaus F-J, Unterrainer M, Beyer L, Brendel M, et al. 68Ga-EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results. Eur J Nucl Med Mol Imaging. 2021:1–10.
Reckamp KL, Frankel PH, Mack PC, Gitlitz BJ, Ruel N, Lara P, et al. Phase II trial of XL184 (cabozantinib) plus erlotinib in patients (pts) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) with progressive disease (PD) on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy: a California Cancer Consortium phase II trial (NCI 9303). American Society of Clinical Oncology; 2014.
Funding
Open Access funding enabled and organized by Projekt DEAL.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This analysis was performed in compliance with the principles of the Declaration of Helsinki and its subsequent amendments. The patient’s relatives have given their consent to the publication of this data. The publication of these data was approved by the institutional ethics board of the LMU Munich. Lena Maria Unterrainer was supported by the Clinician Scientist Program of the LMU Munich.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Oncology - General
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Unterrainer, L.M., Todica, A., Beyer, L. et al. 68Ga-EMP-100 PET/CT—a novel method for non-invasive assessment of c-MET expression in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 50, 628–629 (2023). https://doi.org/10.1007/s00259-022-05995-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-022-05995-3